Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.

@article{Tan2010AssessmentOC,
  title={Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.},
  author={Tricia M.M Tan and In{\^e}s Zimbarra Cabrita and Davina Hensman and Joanna Grogono and Waljit S. Dhillo and Kevin C. R. Baynes and Joseph Eliahoo and Karim Meeran and Stephen Robinson and Petros Nihoyannopoulos and Niamh M. Martin},
  journal={Clinical endocrinology},
  year={2010},
  volume={73 3},
  pages={369-74}
}
OBJECTIVE Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy. DESIGN Cross-sectional, two-dimensional echocardiographic study performed by a single echocardiographer. PATIENTS Seventy-two patients (median age 36… CONTINUE READING

3 Figures & Tables

Connections & Topics

Mentioned Connections BETA
There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson 's disease .
There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson 's disease .
Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia .
This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy .
Our data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy .
This study therefore supports continued use of low - dose cabergoline for patients with hyperprolactinaemia .
Seventy - two patients ( median age 36 years , 19 men ) receiving cabergoline for hyperprolactinaemia , and 72 controls prospectively matched for age , sex and cardiovascular risk factors .
Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia .
There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson 's disease .
All Topics